Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN® (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
STEGLUJAN® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1)]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2)].
- generic_name
- ertugliflozin and sitagliptin
- product_names
- ertugliflozin and sitagliptin
- ndc
- 0006-5367, 0006-5367-03, 0006-5367-06, 0006-5367-07, 0006-5367-08, 0006-5367-09, 0006-5368, 0006-5368-03, 0006-5368-06, 0006-5368-07, 0006-5368-08, 0006-5368-09
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en